<DOC>
	<DOCNO>NCT00607321</DOCNO>
	<brief_summary>To assess feasibility safety Medtronic Bifurcation Stent System treatment single de novo bifurcation lesion native coronary artery reference vessel diameter ( RVD ) proximal main vessel 3.8 - 4.3 mm , distal main branch 3.0 - 3.5 mm , side branch RVD 2.5 mm .</brief_summary>
	<brief_title>Bare Metal Bifurcation Stent Clinical Trial Humans</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>General Inclusion Criteria Candidate percutaneous coronary intervention &amp; emergent coronary artery bypass graft surgery Clinical evidence ischemic heart disease positive functional study Female patient childbearing potential negative pregnancy test within 7 day trial procedure Patient patient 's legal representative provide write informed consent Patient agree comply followup evaluation Angiographic Inclusion Criteria Target lesion ia single de novo bifurcation lesion involve native coronary artery reference vessel diameter proximal main 3.8 4.3 mm , distal main 3.0 3.5 mm , &amp; side branch RVD 2.5 mm Acceptable target lesion lengths combination : &lt; 16mm proximally carina proximal main vessel &lt; 16mm distally carina distal main branch &lt; 12mm carina side branch Target lesion main vessel stenosis &gt; 50 % &lt; 100 % Target vessel ( TIMI ) flow &gt; 2 General Exclusion Criteria Known hypersensitivity/contraindication aspirin , heparin bivalirudin , clopidogrel ticlopidine , cobalt , nickel , chromium , molybdenum , sensitivity contrast medium , ca n't adequately premedicated Platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell ( WBC ) count &lt; 3,000 cells/mm³ within 7 day prior index procedure Serum creatinine level &gt; 170 micromol/L within 7 day prior index procedure Evidence acute MI within 72 hour intend trial procedure ( define : QWMI NQWMI CK enzymes &gt; 2X laboratory upper limit normal presence elevate CKMB ( amount laboratory upper limit normal ) Previous stenting anywhere target vessel PCI nontarget vessel within 30 day prior procedure result MACE event . If non target vessel stent implant within 72 hour prior index procedure , 2 post procedural serial CK CKMB measurement must investigational site 's upper limit normal . PCI nontarget vessel within 24 hour prior procedure Planned PCI vessel within 30 day postprocedure Planned PCI target vessel within 6 month postprocedure During index procedure , target lesion require treatment device PTCA cut balloon prior stent placement Documented leave ventricular ejection fraction ( LVEF ) &lt; 30 % recent evaluation . History stroke transient ischemic attack ( TIA ) within prior 6 month Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month History bleed diathesis coagulopathy refuse blood transfusion Concurrent medical condition life expectancy &lt; 12 month Currently participate investigational drug device trial 's complete primary endpoint clinically interfere current trial endpoint ; require coronary angiography , IVUS coronary artery imaging procedure . Angiographic Exclusion Criteria Bifurcation angle &gt; 90 degree visual estimate Target lesion locate native vessel saphenous vein graft left/right internal mammary artery ( LIMA/RIMA ) bypass Significant stenosis ( &gt; 50 % ) proximal distal target lesion might require revascularization impede run . Target vessel excessively tortuous ( two bend &gt; 90º reach target lesion ) Target lesion follow characteristic : Lesion location aortoostial , unprotected leave main lesion , within 5 mm origin leave anterior descending ( LAD ) , leave circumflex ( LCX ) , right coronary artery ( RCA ) . Severely calcified Evidence thrombus Coexistence unprotected leave main coronary artery disease ( obstruction &gt; 50 % leave main coronary artery )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>restenosis</keyword>
	<keyword>Coronary Disease</keyword>
	<keyword>Coronary Arteriosclerosis</keyword>
	<keyword>Arterial Occlusive Diseases</keyword>
</DOC>